| Literature DB >> 29563152 |
Alexander Hamilton1, Quan Zhang1, Albert Salehi2, Mara Willems1, Jakob G Knudsen1, Anna K Ringgaard3,4, Caroline E Chapman1, Alejandro Gonzalez-Alvarez1, Nicoletta C Surdo5, Manuela Zaccolo5, Davide Basco6, Paul R V Johnson1,7, Reshma Ramracheya1, Guy A Rutter8, Antony Galione9, Patrik Rorsman10,2,7, Andrei I Tarasov10,7.
Abstract
Adrenaline is a powerful stimulus of glucagon secretion. It acts by activation of β-adrenergic receptors, but the downstream mechanisms have only been partially elucidated. Here, we have examined the effects of adrenaline in mouse and human α-cells by a combination of electrophysiology, imaging of Ca2+ and PKA activity, and hormone release measurements. We found that stimulation of glucagon secretion correlated with a PKA- and EPAC2-dependent (inhibited by PKI and ESI-05, respectively) elevation of [Ca2+]i in α-cells, which occurred without stimulation of electrical activity and persisted in the absence of extracellular Ca2+ but was sensitive to ryanodine, bafilomycin, and thapsigargin. Adrenaline also increased [Ca2+]i in α-cells in human islets. Genetic or pharmacological inhibition of the Tpc2 channel (that mediates Ca2+ release from acidic intracellular stores) abolished the stimulatory effect of adrenaline on glucagon secretion and reduced the elevation of [Ca2+]i Furthermore, in Tpc2-deficient islets, ryanodine exerted no additive inhibitory effect. These data suggest that β-adrenergic stimulation of glucagon secretion is controlled by a hierarchy of [Ca2+]i signaling in the α-cell that is initiated by cAMP-induced Tpc2-dependent Ca2+ release from the acidic stores and further amplified by Ca2+-induced Ca2+ release from the sarco/endoplasmic reticulum.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29563152 PMCID: PMC6258900 DOI: 10.2337/db17-1102
Source DB: PubMed Journal: Diabetes ISSN: 0012-1797 Impact factor: 9.461